Literature DB >> 14703120

3D-QSAR and docking studies on 4-anilinoquinazoline and 4-anilinoquinoline epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors.

Haregewein Assefa1, Shantaram Kamath, John K Buolamwini.   

Abstract

The overexpression and/or mutation of the epidermal growth factor receptor (EGFR) tyrosine kinase has been observed in many human solid tumors, and is under intense investigation as a novel anticancer molecular target. Comparative 3D-QSAR analyses using different alignments were undertaken employing comparative molecular field analysis (CoMFA) and comparative molecular similarity analysis (CoMSIA) for 122 anilinoquinazoline and 50 anilinoquinoline inhibitors of EGFR kinase. The SYBYL multifit alignment rule was applied to three different conformational templates, two obtained from a MacroModel Monte Carlo conformational search, and one from the bound conformation of erlotinib in complex with EGFR in the X-ray crystal structure. In addition, a flexible ligand docking alignment obtained with the GOLD docking program, and a novel flexible receptor-guided consensus dynamics alignment obtained with the DISCOVER program in the INSIGHTII modeling package were also investigated. 3D-QSAR models with q2 values up to 0.70 and r2 values up to 0.97 were obtained. Among the 4-anilinoquinazoline set, the q2 values were similar, but the ability of the different conformational models to predict the activities of an external test set varied considerably. In this regard, the model derived using the X-ray crystallographically determined bioactive conformation of erlotinib afforded the best predictive model. Electrostatic, hydrophobic and H-bond donor descriptors contributed the most to the QSAR models of the 4-anilinoquinazolines, whereas electrostatic, hydrophobic and H-bond acceptor descriptors contributed the most to the 4-anilinoquinoline QSAR, particularly the H-bond acceptor descriptor. A novel receptor-guided consensus dynamics alignment has also been introduced for 3D-QSAR studies. This new alignment method may incorporate to some extent ligand-receptor induced fit effects into 3D-QSAR models.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14703120     DOI: 10.1023/b:jcam.0000004622.13865.4f

Source DB:  PubMed          Journal:  J Comput Aided Mol Des        ISSN: 0920-654X            Impact factor:   3.686


  24 in total

1.  Kinase inhibitors and the case for CH...O hydrogen bonds in protein-ligand binding.

Authors:  Albert C Pierce; Kathryn L Sandretto; Guy W Bemis
Journal:  Proteins       Date:  2002-12-01

2.  Three-dimensional quantitative structure-activity relationship analyses using comparative molecular field analysis and comparative molecular similarity indices analysis to elucidate selectivity differences of inhibitors binding to trypsin, thrombin, and factor Xa.

Authors:  M Böhm; J St rzebecher; G Klebe
Journal:  J Med Chem       Date:  1999-02-11       Impact factor: 7.446

3.  Development and validation of a genetic algorithm for flexible docking.

Authors:  G Jones; P Willett; R C Glen; A R Leach; R Taylor
Journal:  J Mol Biol       Date:  1997-04-04       Impact factor: 5.469

4.  Molecular similarity indices in a comparative analysis (CoMSIA) of drug molecules to correlate and predict their biological activity.

Authors:  G Klebe; U Abraham; T Mietzner
Journal:  J Med Chem       Date:  1994-11-25       Impact factor: 7.446

Review 5.  The EGF receptor family as targets for cancer therapy.

Authors:  J Mendelsohn; J Baselga
Journal:  Oncogene       Date:  2000-12-27       Impact factor: 9.867

6.  Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor.

Authors:  F Ciardiello; R Caputo; R Bianco; V Damiano; G Pomatico; S De Placido; A R Bianco; G Tortora
Journal:  Clin Cancer Res       Date:  2000-05       Impact factor: 12.531

7.  Tyrosine kinase inhibitors. 5. Synthesis and structure-activity relationships for 4-[(phenylmethyl)amino]- and 4-(phenylamino)quinazolines as potent adenosine 5'-triphosphate binding site inhibitors of the tyrosine kinase domain of the epidermal growth factor receptor.

Authors:  G W Rewcastle; W A Denny; A J Bridges; H Zhou; D R Cody; A McMichael; D W Fry
Journal:  J Med Chem       Date:  1995-09-01       Impact factor: 7.446

Review 8.  Rational design of potent and selective EGFR tyrosine kinase inhibitors as anticancer agents.

Authors:  S Ghosh; X P Liu; Y Zheng; F M Uckun
Journal:  Curr Cancer Drug Targets       Date:  2001-08       Impact factor: 3.428

9.  Tyrosine kinase inhibitors. 9. Synthesis and evaluation of fused tricyclic quinazoline analogues as ATP site inhibitors of the tyrosine kinase activity of the epidermal growth factor receptor.

Authors:  G W Rewcastle; B D Palmer; A J Bridges; H D Showalter; L Sun; J Nelson; A McMichael; A J Kraker; D W Fry; W A Denny
Journal:  J Med Chem       Date:  1996-02-16       Impact factor: 7.446

10.  Structure of the epidermal growth factor receptor kinase domain alone and in complex with a 4-anilinoquinazoline inhibitor.

Authors:  Jennifer Stamos; Mark X Sliwkowski; Charles Eigenbrot
Journal:  J Biol Chem       Date:  2002-08-23       Impact factor: 5.157

View more
  14 in total

1.  Design and synthesis of novel Gefitinib analogues with improved anti-tumor activity.

Authors:  Xiaoqing Wu; Mingdong Li; Yang Qu; Wenhua Tang; Youguang Zheng; Jiqin Lian; Min Ji; Liang Xu
Journal:  Bioorg Med Chem       Date:  2010-04-21       Impact factor: 3.641

2.  Design, synthesis, and in vitro antitumor activity evaluation of novel 4-pyrrylamino quinazoline derivatives.

Authors:  Xiaoqing Wu; Mingdong Li; Wenhua Tang; Youguang Zheng; Jiqin Lian; Liang Xu; Min Ji
Journal:  Chem Biol Drug Des       Date:  2011-10-24       Impact factor: 2.817

3.  In silico QSAR studies of anilinoquinolines as EGFR inhibitors.

Authors:  Farhan Ahmad Pasha; Muhammad Muddassar; Anil Kumar Srivastava; Seung Joo Cho
Journal:  J Mol Model       Date:  2009-07-10       Impact factor: 1.810

4.  Building 2D classification models and 3D CoMSIA models on small-molecule inhibitors of both wild-type and T790M/L858R double-mutant EGFR.

Authors:  Donghui Huo; Hongzhao Wang; Zijian Qin; Yujia Tian; Aixia Yan
Journal:  Mol Divers       Date:  2021-10-12       Impact factor: 2.943

5.  Databases and QSAR for cancer research.

Authors:  Adeel Malik; Hemajit Singh; Munazah Andrabi; Syed Akhtar Husain; Shandar Ahmad
Journal:  Cancer Inform       Date:  2007-02-15

6.  Quinoline: A versatile heterocyclic.

Authors:  Akranth Marella; Om Prakash Tanwar; Rikta Saha; Mohammad Rahmat Ali; Sandeep Srivastava; Mymoona Akhter; Mohammad Shaquiquzzaman; Mohammad Mumtaz Alam
Journal:  Saudi Pharm J       Date:  2012-03-29       Impact factor: 4.330

Review 7.  Cheminfomatic-based Drug Discovery of Human Tyrosine Kinase Inhibitors.

Authors:  Terry-Elinor Reid; Joseph M Fortunak; Anthony Wutoh; Xiang Simon Wang
Journal:  Curr Top Med Chem       Date:  2016       Impact factor: 3.295

8.  Insights into the EGFR SAR of N-phenylquinazolin-4-amine-derivatives using quantum mechanical pairwise-interaction energies.

Authors:  Saw Simeon; Nathjanan Jongkon; Warot Chotpatiwetchkul; M Paul Gleeson
Journal:  J Comput Aided Mol Des       Date:  2019-09-07       Impact factor: 3.686

Review 9.  Current progress in Structure-Based Rational Drug Design marks a new mindset in drug discovery.

Authors:  Valère Lounnas; Tina Ritschel; Jan Kelder; Ross McGuire; Robert P Bywater; Nicolas Foloppe
Journal:  Comput Struct Biotechnol J       Date:  2013-04-02       Impact factor: 7.271

10.  Comparative molecular field analysis (CoMFA) and comparative molecular similarity indices analysis (CoMSIA) of thiazolone derivatives as hepatitis C virus NS5B polymerase allosteric inhibitors.

Authors:  Beilei Lei; Juan Du; Shuyan Li; Huanxiang Liu; Yueying Ren; Xiaojun Yao
Journal:  J Comput Aided Mol Des       Date:  2008-08-21       Impact factor: 3.686

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.